Inari Medical Inc

Inari Medical Inc Stock Forecast & Price Prediction

Live Inari Medical Inc Stock (NARI) Price
$50.05

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$50.05

P/E Ratio

-1,668.33

Volume Traded Today

$469,639

Dividend

Dividends not available for NARI

52 Week High/low

67.13/36.73

Inari Medical Inc Market Cap

$2.90B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $NARI ๐Ÿ›‘

Before you buy NARI you'll want to see this list of ten stocks that have huge potential. Want to see if NARI made the cut? Enter your email below

NARI Summary

From what 0 stock analysts predict, the share price for Inari Medical Inc (NARI) might increase by 29.01% in the next year. This is based on a 12-month average estimation for NARI. Price targets go from $48 to $86. The majority of stock analysts believe NARI is a sell. Please note analyst price targets are not guaranteed and could be missed completely.

NARI Analyst Ratings

About 0 Wall Street analysts have assignedNARI 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Inari Medical Inc to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on NARI. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

NARI stock forecast by analyst

These are the latest 20 analyst ratings of NARI.

Analyst/Firm

Rating

Price Target

Change

Date

Mike Matson
Needham

Hold


Reiterates

Oct 30, 2024
Mike Matson
Needham

Hold


Reiterates

Oct 29, 2024
Richard Newitter
Truist Securities

Hold

$50

Maintains

Oct 29, 2024
Adam Maeder
Piper Sandler

Neutral

$52

Maintains

Oct 29, 2024
William Plovanic
Canaccord Genuity

Buy

$74

Maintains

Oct 29, 2024
David Rescott
Baird

Outperform

$67

Maintains

Oct 29, 2024
Richard Newitter
Truist Securities

Hold

$46

Maintains

Oct 14, 2024
Mike Matson
Needham

Hold


Reiterates

Oct 9, 2024
Mathew Blackman
Stifel

Hold

$50

Initiates

Sep 17, 2024
Mike Kratky
Leerink Partners

Market Perform

$47

Initiates

Sep 3, 2024
Adam Maeder
Piper Sandler

Neutral

$50

Maintains

Aug 26, 2024
Pito Chickering
Deutsche Bank

Buy

$68

Initiates

Aug 9, 2024
William Plovanic
Canaccord Genuity

Buy

$71

Maintains

Jul 31, 2024
Mike Matson
Needham

Hold


Reiterates

Jul 31, 2024
David Rescott
Baird

Outperform

$63

Maintains

Jul 31, 2024
Richard Newitter
Truist Securities

Hold

$55

Reiterates

Jul 31, 2024
Larry Biegelsen
Wells Fargo

Overweight

$65

Maintains

Jul 31, 2024
Margaret Andrew
William Blair

Outperform


Initiates

Jul 25, 2024
Mike Matson
Needham

Hold


Downgrade

Jul 18, 2024
Richard Newitter
Truist Securities

Hold

$60

Maintains

Jul 16, 2024

NARI Company Information

What They Do: Develops innovative thrombectomy devices for vascular treatments.

Business Model: Inari Medical, Inc. generates revenue by designing, manufacturing, and selling catheter-based mechanical thrombectomy devices aimed at treating various vascular conditions such as deep vein thrombosis and pulmonary embolism. The company targets healthcare professionals including interventional radiologists, cardiologists, and vascular surgeons, who utilize these devices in clinical settings.

Other Information: Founded in 2011 and headquartered in Irvine, California, Inari Medical was previously known as Inceptus Newco1 Inc. The company has developed several specialized systems including ClotTriever, FlowTriever, InThrill, and LimFlow, catering to specific medical needs, which positions it well within the growing interventional medical device market.
NARI
Inari Medical Inc (NARI)

When did it IPO

2020

Staff Count

1,300

Country

United States

Sector/Industry

Healthcare/Medical Devices

CEO

Mr. Andrew J. Hykes

Market Cap

$2.90B

Inari Medical Inc (NARI) Financial Data

In 2023, NARI generated $493.6M in revenue, which was a increase of 28.73% from the previous year. This can be seen as a signal that NARI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$139.7M

Revenue From 2021

$277.0M

98.31 %
From Previous Year

Revenue From 2022

$383.5M

38.45 %
From Previous Year

Revenue From 2023

$493.6M

28.73 %
From Previous Year
  • Revenue TTM $574.5M
  • Operating Margin TTM -4.3%
  • Gross profit TTM $434.6M
  • Return on assets TTM -3.2%
  • Return on equity TTM -17.7%
  • Profit Margin -13.7%
  • Book Value Per Share 7.44%
  • Market capitalisation $2.90B
  • Revenue for 2021 $277.0M
  • Revenue for 2022 $383.5M
  • Revenue for 2023 $493.6M
  • EPS this year (TTM) $-1.35

Inari Medical Inc (NARI) Latest News

News Image

Mon, 28 Oct 2024

Sentiment - NEUTRAL

Source - Seeking Alpha

Summary - Inari Medical, Inc. (NASDAQ:NARI) will hold its Q3 2024 earnings conference call on October 28, 2024, at 4:30 PM ET, featuring key company executives and analysts from various firms.

Why It Matters - The earnings call indicates Inari Medical's financial performance and strategic direction, impacting stock valuation and investor sentiment in the medical device sector.

News Image

Mon, 28 Oct 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Inari Medical, Inc. (NASDAQ: NARI) reported its Q3 2024 financial results, continuing its focus on treating patients with venous and other diseases.

Why It Matters - Inari Medical's Q3 financial results provide insights into its performance and growth potential, impacting stock valuation and investor sentiment in the medical device sector.

News Image

Mon, 28 Oct 2024

Sentiment - NEGATIVE

Source - Zacks Investment Research

Summary - Inari Medical, Inc. (NARI) reported a quarterly loss of $0.13 per share, slightly worse than the expected loss of $0.12, compared to earnings of $0.05 per share in the same quarter last year.

Why It Matters - Inari Medical's larger-than-expected quarterly loss signals potential operational challenges, impacting investor confidence and stock performance. Year-over-year earnings decline raises further concerns.

News Image

Tue, 29 Oct 2024

Sentiment - NEGATIVE

Source - Zacks Investment Research

Summary - NARI's Q3 results show increased revenues but poor profitability, with contracting gross margins and ongoing operating losses.

Why It Matters - NARI's revenue growth contrasts with declining gross margins and ongoing losses, signaling potential operational challenges and impacting future profitability and investor confidence.

News Image

Tue, 29 Oct 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - The company achieved a primary endpoint win, supported by strong clinical outcomes and effective use of hospital resources.

Why It Matters - Positive clinical outcomes and efficient resource use can enhance a company's credibility and market position, potentially leading to increased revenue and stock performance.

News Image

Mon, 21 Oct 2024

Sentiment - NEGATIVE

Source - Zacks Investment Research

Summary - Inari Medical (NARI) is expected to lack the necessary factors for a potential earnings beat in its upcoming report, signaling caution for investors.

Why It Matters - Inari Medical's lack of key ingredients for an earnings beat suggests potential underperformance, impacting stock price and investor sentiment.

...

NARI Frequently asked questions

The highest forecasted price for NARI is $86 from at .

The lowest forecasted price for NARI is $48 from from

The NARI analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.